4.3 Article

Association Study of Serotonin 3 Receptor Subunit Gene Variants in Antipsychotic-Induced Weight Gain

期刊

NEUROPSYCHOBIOLOGY
卷 74, 期 3, 页码 169-175

出版社

KARGER
DOI: 10.1159/000457903

关键词

Serotonin 3A and 3B receptor genes (HTR3A, HTR3B); Schizophrenia; Antipsychotic-induced weight gain; Pharmacogenetics

资金

  1. Sunovion Novartis
  2. TEVA
  3. Bioline Rx
  4. BI
  5. Envivo
  6. Companion Dx
  7. Janssen Pharma
  8. Lundbeck
  9. Allon
  10. Biomarin
  11. Eli Lilly
  12. F. Hoffmann-La Roche/Genentech
  13. GlaxoSmithKline
  14. Merck
  15. Novartis
  16. Pfizer
  17. Psychogenics
  18. Sepracor (Sunovion)
  19. Targacept
  20. Canadian Institutes of Health Research [MOP 142192]
  21. National Institutes of Health
  22. Centre for Addiction and Mental Health Foundation
  23. Canadian Biomarker Integration Network in Depression
  24. Ontario Brain Institute

向作者/读者索取更多资源

Background: Schizophrenia (SCZ) is a chronic severe neuropsychiatric disorder, where pharmacological treatment has been hindered by adverse effects, including antipsychotic-induced weight gain (AIWG) and related complications. Genetic studies have been exploring the appetite regulation and energy homeostasis pathways in AIWG with some promising leads. The serotonin system has been shown to participate in these pathways. Methods: In the current study, we examined single nucleotide polymorphisms across the serotonin receptor genes HTR3A and HTR3B. Prospective weight change was assessed for a total of 149 SCZ patients of European ancestry. Results: We did not find the tested HTR3A or HTR3B gene markers to be associated with AIWG in our sample. Conclusion: Our preliminary findings suggest that these receptors may not play a major role in predicting AIWG. (C) 2017 S. Karger AG, Basel

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据